We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-14.00 | -0.12% | 12,156.00 | 12,126.00 | 12,128.00 | 12,258.00 | 12,114.00 | 12,114.00 | 1,961,686 | 16:35:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.57 | 188.01B |
TIDMAZN
RNS Number : 5771Y
AstraZeneca PLC
02 January 2020
02 January 2020 15:00 GMT
Transparency Directive
Voting Rights and Capital
The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 December 2019 the issued share capital of AstraZeneca PLC with voting rights is 1,312,137,976 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,312,137,976.
The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Media Relations Gonzalo Viña +44 203 749 5916 Rob Skelding Oncology +44 203 749 5821 Rebecca Einhorn Oncology +1 301 518 4122 Matt Kent BioPharmaceuticals +44 203 749 5906 Jennifer Hursit Other +44 203 749 5762 Christina Malmberg Hägerstrand Sweden +46 8 552 53 106 Michele Meixell US +1 302 885 2677 Investor Relations Thomas Kudsk Larsen +44 203 749 5712 Henry Wheeler Oncology +44 203 749 5797 Christer Gruvris BioPharmaceuticals (Cardiovascular, Metabolism) +44 203 749 5711 BioPharmaceuticals (Renal) Environmental, Social and Nick Stone Governance +44 203 749 5716 BioPharmaceuticals (Respiratory) Josie Afolabi Other medicines +44 203 749 5631 Finance Craig Marks Fixed income +44 7881 615 764 Corporate access Jennifer Kretzmann Retail investors +44 203 749 5824 US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TVRFLFSFLFIFIII
(END) Dow Jones Newswires
January 02, 2020 10:00 ET (15:00 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions